Heart failure with preserved ejection fraction: Current understanding and emerging concepts

Current Opinion in Cardiology

Volumn 28, Issue 2, 2013, Pages 187-196

  Liu, Yingwei ^a   Haddad, Tony ^a   Dwivedi, Girish ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

diastolic heart failure; heart failure; heart failure with preserved ejection fraction; pathophysiology

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CA 125 ANTIGEN; CARNITINE; CARVEDILOL; COLLAGEN TYPE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FATTY ACID BINDING PROTEIN; GELATINASE B; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 6; INTERLEUKIN 8; IRBESARTAN; IVABRADINE; LIOTHYRONINE; LOOP DIURETIC AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; NEBIVOLOL; OSTEOPONTIN; PLACEBO; SCLEROPROTEIN; SILDENAFIL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CLINICAL EVALUATION; COMORBIDITY; DIURETIC THERAPY; DRUG EFFECT; DRUG EFFICACY; ENDURANCE TRAINING; EXERCISE TEST; HEART ATRIUM PACING; HEART FAILURE; HEART FAILURE WIT H PRESERVED EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH PRESERVEE EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; INVASIVE PROCEDURE; KINESIOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; COMORBIDITY; EXERCISE TEST; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84873432602     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32835c5492     Document Type: Review

References (80)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics Y 2010 update: A report from the American Heart Association. Circulation 2010; 121:e46-e215.
2. Hunt SA, Abraham WT, Chin MH, et al., American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154-e235.
3. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251-259.
4. Liao L, Jollis JG, Anstrom KJ, et al. Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med 2006; 166:112-118.
5. Liao L, Anstrom KJ, Gottdiener JS, et al. Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. Am Heart J 2007; 153:245-252.
6. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288:2144-2150.
7. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: Influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002; 137:631-639.
8. Steinberg BA, Zhao X, Heidenreich PA, et al., Get With the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126:65-75.
9. Klapholz M, Maurer M, Lowe AM, et al., New York Heart Failure Consortium. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: Results of the New York Heart Failure Registry. J Am Coll Cardiol 2004; 43:1432-1438.
10. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59:998-1005.
11. Ho JE, Gona P, Pencina MJ, et al. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J 2012; 33:1734-1741.
12. Lam CS, Carson PE, Anand IS, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: The Irbesartan in Heart Failure with Preserved Ejection Fraction (IPRESERVE) trial. Circ Heart Fail 2012; 5:571-578.
13. Phan TT, Shivu GN, Abozguia K, et al. Left ventricular torsion and strain patterns in heart failure with normal ejection fraction are similar to age-related changes. Eur J Echocardiogr 2009; 10:793-800.
14. Sanderson JE. Heart failure with a normal ejection fraction. Heart 2007; 93:155-158.
15. Yip GW, Zhang Q, Xie JM, et al. Resting global and regional left ventricular contractility in patients with heart failure and normal ejection fraction: Insights from speckle-tracking echocardiography. Heart 2011; 97:287-294.
16. Cioffi G, Senni M, Tarantini L, et al. Analysis of circumferential and longitudinal left ventricular systolic function in patients with nonischemic chronic heart failure and preserved ejection fraction (from the CARRY-IN-HFpEF study). Am J Cardiol 2012; 109:383-389.
17. Dunlay SM, Roger VL, Weston SA, et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 2012; 5:720-726.
18. Phan TT, Shivu GN, Abozguia K, et al. The pathophysiology of heart failure with preserved ejection fraction: from molecular mechanisms to exercise haemodynamics. Int J Cardiol 2012; 158:337-343.
19. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32:670-679.
20. Tan YT, Wenzelburger F, Lee E, et al. The pathophysiology of heart failure with normal ejection fraction: Exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol 2009; 54:36-46.
21. Kusunose K, Motoki H, Popovic ZB, et al. Independent association of left atrial function with exercise capacity in patients with preserved ejection fraction. Heart 2012; 98:1311-1317.
22. Phan TT, Abozguia K, Nallur Shivu G, et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 2009; 54:402-409.
23. Wood P, Piran S, Liu PP. Diastolic heart failure: progress, treatment challenges, and prevention. Can J Cardiol 2011; 27:302-310.
24. Van Heerebeek L, Franssen CP, Hamdani N, et al. Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep 2012; 9:293-302.
25. Udelson JE. Heart failure with preserved ejection fraction. Circulation 2011; 124:e540-e543.
26. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998; 19:990-1003.
27. Vasan RS, Levy D. Defining diastolic heart failure: A call for standardized diagnostic criteria. Circulation 2000; 101:2118-2121.
28. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28:2539-2550.
29. Leong DP, De Pasquale CG, Selvanayagam JB. Heart failure with normal ejection fraction: The complementary roles of echocardiography and CMR imaging. JACC Cardiovasc Imaging 2010; 3:409-420.
30. Almeida P, Rodrigues J, Lourenço P, et al. Prognostic significance of applying the European Society of Cardiology consensus algorithm for heart failure with preserved systolic function diagnosis. Clin Cardiol 2012; 35:770-778. doi: 10.1002/clc.22044. [Epub ahead of print]
31. Welles CC, Ku IA, Kwan DM, et al. Left atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: longitudinal data from the Heart and Soul Study. J Am Coll Cardiol 2012; 59:673-680.
32. Ohtani T, Mohammed SF, Yamamoto K, et al. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. Eur Heart J 2012; 33:1742-1749.
33. Penicka M, Bartunek J, Trakalova H, et al. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: A pressureYvolume loop analysis. J Am Coll Cardiol 2010; 55:1701-1710.
34. Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3:588-595.
35. Donal E, Thebault C, Lund LH, et al. Heart failure with a preserved ejection fraction additive value of an exercise stress echocardiography. Eur Heart J Cardiovasc Imaging 2012; 13:656-665.
36. Andersen MJ, Ersbøll M, Bro-Jeppesen J, et al. Exercise hemodynamics in patients with and without diastolic dysfunction and preserved ejection fraction after myocardial infarction. Circ Heart Fail 2012; 5:444-451.
37. Tartiè re-Kesri L, Tartiè re JM, Logeart D, et al. Increased proximal arterial stiffness and cardiac response with moderate exercise in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 2012; 59: 455-461.
38. Jeevanantham V, Shrivastava R, Nannapaneni S, et al. Elevated B-type natriuretic peptide level: Use with caution in patients with multiple co-morbidities and presenting with dyspnea. Indian Heart J 2007; 59:64-68.
39. Packer M. Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. Circ Heart Fail 2011; 4:538-540.
40. Carlsen CM, Bay M, Kirk V, et al. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: A 10-year analysis from the Copenhagen Hospital Heart Failure Study. Eur J Heart Fail 2012; 14:240-247.
41. Anand IS, Rector TS, Cleland JG, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 2011; 4:569-577.
42. Krum H, Elsik M, Schneider HG, et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen substudy. Circ Heart Fail 2011; 4:561-568.
43. Collier P, Watson CJ, Voon V, et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 2011; 13:1087-1095.
44. Chu JW, Jones GT, Tarr GP, et al. Plasma active matrix metalloproteinase 9 and indices of diastolic function in patients with preserved systolic function. Int J Cardiol 2012. [Epub ahead of print]
45. Selvaraj S, Klein I, Danzi S, et al. Association of serum triiodothyronine with Btype natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. Am J Cardiol 2012; 110: 234-239.
46. Cleland JG, Taylor J, Freemantle N, et al. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: A report from the PEP-CHF study. Eur J Heart Fail 2012; 14:487-494.
47. Kutsuzawa D, Arimoto T, Watanabe T, et al. Ongoing myocardial damage in patients with heart failure and preserved ejection fraction. J Cardiol 2012; 60:454-461.
48. Santhanakrishnan R, Chong JP, Ng TP, et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012; 14:1338-1347.
49. Hung CL, Hung TC, Liu CC, et al. Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women. Am J Cardiol 2012; 110:993-1000.
50. Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011; 4:27-35.
51. Parissis JT, Ikonomidis I, Rafouli-Stergiou P, et al. Clinical characteristics and predictors of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction. Am J Cardiol 2011; 107:79-84.
52. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: Results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4:324-331.
53. Buiciuc O, Rusinaru D, Lé vy F, et al. Low systolic blood pressure at admission predicts long-term mortality in heart failure with preserved ejection fraction. J Card Fail 2011; 17:907-915.
54. Miura M, Shiba N, Nochioka K, Shimokawa H, CHART-2 Investigators. Urinary albumin excretion in heart failure with preserved ejection fraction: An interim analysis of the CHART 2 study. Eur J Heart Fail 2012; 14:367-376.
55. McAlister FA, Ezekowitz J, Tarantini L, et al., Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) Investigators. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: Impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 2012; 5:309-314.
56. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355:260-269.
57. Rickenbacher P, Pfisterer M, Burkard T, et al.; for the TIME-CHF Investigators. Why and how do elderly patients with heart failure die? Insights from the TIME-CHF study. Eur J Heart Fail 2012; 14:1218-1229.
58. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. Eur Heart J 2012; 33:1750-1757.
59. Hobbs FD, Roalfe AK, Davis RC, et al. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 2007; 28:1128-1134.
60. Zile MR, Gaasch WH, Anand IS, et al., I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: Results from the Irbesartan in Heart Failure With Preserved Ejection Fraction study (I-Preserve). Circulation 2010; 121:1393-1405.
61. Hamaguchi S, Kinugawa S, Sobirin MA, et al., JCARE-CARD Investigators. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: Report from the registry of hospitalized heart failure patients. Circ J 2012; 76:1662-1669.
62. Cleland JG, Tendera M, Adamus J, et al., on behalf of PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27:2338-2345.
63. Yusuf S, Pfeffer MA, Swedberg K, et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362:777-781.
64. Massie BM, Carson PE, McMurray JJ, et al., I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359:2456-2467.
65. Flather MD, Shibata MC, Coats AJ, et al., SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26:215-225.
66. Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 2011; 17:634-642.
67. Conraads VM, Metra M, Kamp O, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: Results of the ELANDD study. Eur J Heart Fail 2012; 14:219-225.
68. Holland DJ, Kumbhani DJ, Ahmed SH, Marwick TH. Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol 2011; 57: 1676-1686.
69. Rector TS, Carson PE, Anand IS, et al., I-PRESERVE Trial Investigators. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the Minnesota living with heart failure questionnaire in the Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial. Circ Heart Fail 2012; 5:217-225.
70. Agarwal V, Briasoulis A, Messerli FH. Effects of reninYangiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. Heart Fail Rev 2012. [Epub ahead of print]
71. Yamamoto K, Origasa H, Hori M; on behalf of the J-DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: The Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2012. [Epub ahead of print]
72. Patel K, Fonarow GC, Kitzman DW, et al. Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: A propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail 2012; 14:1179-1188.
73. Guazzi M, Vicenzi M, Arena Rand Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124:164-174.
74. Solomon SD, Zile M, Pieske B, et al., for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 doubleblind randomised controlled trial. Lancet 2012; 380:1387-1395.
75. Omori Y, Ohtani T, Sakata Y, et al. L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens 2012; 30:1834-1844.
76. Reil JC, Hohl M, Reil GH, et al. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 2012 [Epub ahead of print].
77. Edelmann F, Gelbrich G, Düngen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: Results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011; 58:1780-1791.
78. Haykowsky MJ, Brubaker PH, Stewart KP, et al. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. J Am Coll Cardiol 2012; 60:120-128.
79. Laurent G, Eicher JC, Mathe A, et al. Permanent left atrial pacing therapy may improve symptoms in heart failure patients with preserved ejection fraction and atrial dyssynchrony: A pilot study prior to a national clinical research programme. Eur J Heart Fail 2012. [Epub ahead of print]
80. West R, Liang L, Fonarow GC, et al. Characterization of heart failure patients with preserved ejection fraction: A comparison between ADHERE-US registry and ADHERE-International registry. Eur J Heart Fail 2011; 13:945-952.